Ladies and gentlemen, thank you for standing by. Welcome to the Brooks Automation Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded, Thursday, November 9, 2017. I would now like to turn the call over to Lindon Robertson, Executive Vice President and Chief Financial Officer for Brooks Automation. Please go ahead, sir.

Thank you, Nelson, and good afternoon, everyone. We would like to welcome each of you to the fourth quarter financial results conference call for the Brooks fiscal year 2017. We will be covering the results of the fourth quarter and fiscal year ended on September 30, and then we will provide an outlook for the first fiscal quarter of 2018 ending December 31, 2017, and we'll provide an update to our target model for 2019. A press release was issued earlier this morning is available at our Investor Relations page of our website, www.brooks.com, as are the illustrated PowerPoint slides that will be used during the prepared comments during the call. I would like to remind everyone that during the course of the call, we will be making a number of forward-looking statements within the meaning of the Private Litigation Securities Act of 1995. There are many factors that may cause actual financial results or other events to differ from those identified in such forward-looking statements. I would refer you to the section of our earnings release titled Safe Harbor Statement, the Safe Harbor slide on the aforementioned PowerPoint presentation on our website and our various filings with the SEC, including our annual reports on Form 10-K and our quarterly reports on Form 10-Q. We made no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today. I would also like to note that we may make reference to a number of non-GAAP financial measures, which are used in addition to, and in conjunction with, results presented in accordance with GAAP. We believe that these non-GAAP measures provide an additional way of viewing aspects of our operations and performance. But when considered with GAAP financial results and the reconciliation of GAAP measures, they provide an even more complete understanding of the Brooks business. Non-GAAP measures should not be relied upon to the exclusion of the GAAP measures themselves. On the call with me today is our Chief Executive Officer, Steve Schwartz. We will open with his remarks on the business environment and our performance highlights and then we'll provide an overview of the fourth quarter and full fiscal year financial results and a summary of our financial outlook for the quarter ending December 31, which is our first quarter of the fiscal year 2018. We will wind up with an update to our 2019 model and then we'll take your questions at the end of those comments. During our prepared remarks, again we will, from time to time, make reference to the slides I mentioned available to everyone on the Investor Relations page of our Brooks website. With that, I'd like to turn the call over now to our CEO, Mr. Steve Schwartz.

Thank you, Lindon. Good morning, everyone, and thank you for joining our call. We're pleased to report Q1 results from very solid quarter that caps an outstanding fiscal 2017, a yeah which we advanced all our strategic initiatives and one that positions us for even stronger fiscal 2018. One year ago at this time, we said that we're in an inflection point and we expressed our confidence and our ability to deliver substantially improved performance in both a rapidly expanding Life Science market and Semiconductor equipment space. As it turned out, we were right, and we are ready. For the year we grew revenue 24% to $693 million with Semiconductor up 20% and Life Sciences up 38%. Two very strong businesses demonstrating exceptional growth. And today, as we look into 2018, we have much the same sentiments. As we see demand from our core markets lining up to be even strong than last year and we are on with new products that are specifically designed to take their place in our customer's technology and production roadmaps. We see the Life Sciences market providing steady rapid growth for us as the even increasing demand for samples is expanding our opportunity both because of the sure number of samples that are collected and stored but also because more and more customers are looking for help from a supplier who can give them a workable solution, so the efficient and precise management of these vast and valuable collections. A collection of samples is not new but the means by which these samples are managed is undergoing a dramatic shift, because the value of the sample is now more than even dependent upon the preservation of the sample in a cold environment and the data and information that must reliably be attached to each…

Great. Thank you, Steve. Please refer now to the PowerPoint slides available on the Brooks website under our Investor Relations tab. To start the remarks, I would like to draw your attention to Slide 3, which is a consolidated view of our fourth quarter operating performance. Our top line revenue was flat sequentially to $182 million, driven by 20% increase in Life Sciences and an expected 5% decline in Semiconductor Solutions. On a year-over-year basis, the $182 million of revenue increased 13%, reflecting Life Sciences revenue growth of 39% and Semiconductor Solutions group of 10%. Life Sciences revenue in the quarter amounted to 24% of our company total. In the GAAP results, earnings per share remained at $0.25 even with the third quarter results. This reflects a benefit from higher gross margins and lower taxes, offset largely by higher operating expenses. The EPS of $0.25 is 62% higher on a year-to-year basis compared to the same period of fiscal 2016. Looking at the non-GAAP picture on the right, let's walk down the P&L. The non-GAAP gross margin increased 130 basis points to 41.3%. We saw a modest increase in Life Sciences margins, but the significant improvement was driven by higher margins in the Semiconductor segment. Operating expenses increased $4.3 million, reflecting growth in both segments. The increase in R&D was driven largely by investments in Life Sciences the increase in the SG&A also reflects further investment in Life Sciences including the July acquisition of PBMMI sample storage business and additional hiring for sales and operations. We also saw an increase across our business in commissions, variable compensation and the non-cash expense for long term incentives plans. Down below operating income, the tax line reflects a 13% non-GAAP tax rate for Q4. Our joint venture income came in at $2.1 million…

Thank you. [Operator Instructions] Our first question comes from the line of Farhan Ahmad with Credit Suisse. Please proceed.

Hi, thanks for taking my questions. Your Life Sciences business has shown a lot of growth recently and you continuing to grow. Can you talk about the synergy going forward between the Life Sciences and your Semi business and does it make sense for the two businesses to exist together company going forward? And how do see the business being evolving?

Hi, Farhan. Yeah, thanks. This is a really good question is one that we spend a lot of time on. Let me give you a couple from a product and technology standpoint, one of the things that this team is doing, they utilize some of the cryogenic capabilities of the company and they've employed now in two different methods in two different designs for cold storage with a third coming. So we have some overlap remaining from a science and technology standpoint, but I think it's been put to good use and it makes for a much more efficient store and it is really well received by the customers. At the sales level, at the business development level, they are pretty separate businesses. And of course as we've grown both business, we still rely on the cash generation capability of really strong Semi business, they help fund growth in both segments. In time, we will always be open to whatever the best thing is for the shareholders. We still have a small Life Sciences business and we're were adequately both capitalized and able to generate cash to support it. But what we will always be looking that in the future for right now good overlap from a technology standpoint and the freedom to - and the ability to fund the growing Life Science business that this really flourishing we think. So right now, we're content with the position that we have but we will pay close attention to this because we've planned a pretty significant growth here and Life Sciences will continue to gain mass and be a more significant part of the company.

Got it. And then just one question on the gross margin for Life Sciences, if I go back a couple of quarters, we were expecting the gross margins at the end of the year to be north of 40% but been about 38%, 39% now. Can you just talk about why the gross margins coming in a little bit lighter than what you were expecting a few quarters ago in the life sciences side of it just impact from acquisitions or is there some mix issues?

Yeah, Farhan. It's a really fair question. And I would emphasize upfront that we are expecting the business to run at 40% overall and better in the near term to get to that 42% to 44% range by 2019. In this period, we have seen a couple of things happened. One, we did have a little more mix of genomics related services. So typically in the past two years, we saw a pretty significant spike in the December quarter but in this quarter, we saw an increase in that and it does bring a bit of lower margins. And then I'll also acknowledge that as Steve highlighted, we did decide to make investment in China so to speak in other words the transaction that we decided to do there did bring our margins down slightly on average. We consider this is a very important space for us that while we have been there this was significant mark key win for us and we think it will be a nice platform to grow inside that region. So it brought our margins down slightly and so what you're seeing us in that 38%. Meanwhile I'll also acknowledge that we have opportunity in the cost area around our infrastructure and consumable space and we continue to integrate and with the latest acquisitions, we think will continue to refine that area. So that's why we have confidence with the business overall, we think some growth areas that you're starting to see around as well as some of the improvements that we see will offset the genomic mix and get us above the 40% and beyond.

Got it. And then one last question on the guidance for the December quarter, you are guiding revenues up, but EPS significantly down, so can you just help us understand what about how do you bridge the EPS?

Yeah. That's a good question. So just if you refer back to the P&L chart, what you'll see is that we do have some impact in the non-operating income. So our tax rate for this past quarter was about 13% and that was a little lower than over the year as we had some discrete levels in this past quarter. But in the quarter coming, we refreshed to the following year. Our guidance on the 20108 year will put us again in the 15% to 20% range. Expectation we have about 18% factored in for the quarter and for the year currently, but it all ranges between 15% to 20%. So that takes us down a little bit. And then we also have lower joint venture income as you saw it soften this past quarter, we're expecting a little more softening in the coming quarter. And then finally and this is I think of important for everyone to recognize, we try to hit is the debt does add some weight to our EPS, in other words about $0.03 in the quarter is the impact of the interest expense. So if you were to factor just the interest expense and which is a change to our model really at least how everybody else is viewing it, you would look for about a $0.03 adjustment, the tax and the joint venture earnings make up the difference.

Great. Thank you, that's all I have.

Thank you, Farhan. I appreciate your analysis.

Thank you. Our next question comes from the line of William March with Janney Montgomery Scott. Please proceed.

Hey, guys. How are you?

Hi, Bill.

So, the first question, could you maybe just talk about the 4titude acquisition and specifically it seems like their products are a little bit more geared towards lab consumables as opposed to what we would think about Brooks's sample storage solutions, so just kind of the strategy behind that and then maybe how does this acquisition open up additional opportunities for M&A maybe in a space adjacent to where you guys have traditionally played?

Sure, Bill. And this is an interesting one for us because without the capabilities that we acquired in the last couple years, it would be a little tougher fit. We did find in our as we canvassed the area around the cold-chain, a couple things, one, as you know in the BioStorage alliance that we have with RECRD [ph] there is a high volume of both storage and in the use of PCR placed there for analysis and ultimately, we have customers now story PCR, formatted samples in cold storage. So we think it's a really good fit and we look as amount of genomic analysis is accelerating that this format is much more prevalent, and it happens to be mainstream in some of our customers and on the analysis side of our business. So we think it's a really good add from that standpoint and the integration by the way going extremely well. One of the things that note is that it allows us also to expand and put something else in the consumables case for the sales before up selling the FluidX capability. So we can leverage and infrastructure we built the sales organization and we're actually contacting the same customers who buy other services and the infrastructure stores from us. So far really good fit, we like the business a great deal, we'll learn a lot more about it as we go, but we anticipate good synergies on the sales side and certainly from the analysis in storage side as well.

Got it. And then on the B3C, could you maybe just talk about, I guess two questions, one, with the recent CAR-T approvals by the FDA, have you seen an increase in contact with customers? And then secondly just could you maybe just talk about how that infrastructure would fit into a company if they had a CAR-T therapy approved and how many freezers would they need from you guys just kind of how that that opportunity looks over the next couple years?

Sure. I can after the first part with a little more clarity excuse me than the second part. Because of the CAR-T and the way that these technologies are advancing, the customers almost self-declaring a little bit easier. So they're pretty easy to find and they are numerous as you can imagine. And so that's the bulk of the penetration. I think one of the thing that has done is this focus rather we went up early adopters early on at a broad audience, we're finding that the cryo is really focused on very specifically some of this immunotherapy. So that that's the focus area for the company, we find a good match there and that's why we talk about 30 different sites with the B3C from an adoption standpoint, that's gaining some momentum and we feel really good about that. In terms of the workflow, it won't be simply an automated store, but it will be how do we continue to protect the samples below the glass transition temperature from storage through transport to ultimately where this sample would be used. We think it's an integral part. This will be a long process to get this qualified into process ultimately that could be used for clinical trial. But you can imagine that if B3C system stored 10,000 samples, you can do arithmetic pretty quickly to understand that that would drive a very significant market opportunity for us. So how those would be distributed, would they be a clinics, would they be at a pharmacy, would they be only in a central location ultimately shipped out? It's yet to be determined, but I think I can tell you that a lot of activity going on to how we take some of these technologies and expand the market. But we're working on the workflow, this is front in center right now.

Great. And then one last one just from on the Semi side of the business kind of what gave you the confidence after you had updated fiscal year 2019 guidance a few months ago on the Semi side of things and to raise it only a couple months later, what are you seeing either from end markets or customers that gives you the confidence to raise those numbers so quickly? Thanks, guys.

Yeah. Let me start on that one. So you said a couple months later, but we've been reiterating the guidance but that guidance, that model was established in the summer of 2016. And we have been holding on to that. And as we've said in the past, we don't quite fully subscribe to the fact that the Semi market has shed all of the cyclical nature. We suspect that we're vulnerable to cycles but in light of the confidence that we're seeing in the industry and among our largest customers talking in the indications of the 2018 and likely into 2019 and where we're seeing specific investments in the Semi that would suggest that the CapEx equipment market is running a above $40 billion on a fairly consistent basis. Then we decided to reflect this into the model. And we've been facing the question for a while well you must be thinking Semi is flat or down based on your model and that's not the case. We believe that we are in a market that grows better than GDP. We've seen over the last two years much better than that because of the change in the capital intensity in the market and it appears to us that that capital intensity does have a good case for sustaining itself going forward. And then with all of that said we caution our investors that we do think that there's still cyclical nature at these levels. So that's why we still on the principle of our model show a modest cycle. When we say flat to 5% market for us 2% the 8% revenue growth, we think that's pretty modest, it could be bigger, it could be lower. And the real purpose of our 2019 model is to show you that if we think this is right down the middle of the road in Semi then what does the rest of our transformation continue to do for our earnings potential. And we think that's pretty significant and we think that's meaningful for the investor and we have gain a lot more confidence where the Semi markets rounded out.

Thanks guys.

Bill, thanks very much.

Thank you. Our next question comes from the line of Edwin Mok with Needham and Company. Please proceed.

Great, guys. Thanks for taking my question. First, I guess once just ask you little bit around the December quarter guidance. From the commentary that's Semi, you expect Semi to be flat, but I think the customer actually some pretty bullish, is that upside for that? And then on the Life Science side, you did the 4titude acquisition, how much of that contribution to the December quarter revenue?

So Edwin, this is Steve. On the Semi side, with the exception of the contamination control business which is as you know really heavily foundry driven, we have pretty high volume, we anticipate that this is to comeback as it probably in the for the middle of calendar 2018, but the remainder of the Semi business we forecast to be up. So we're very positive on all parts of the business but the increase in the remainder - in the bulk of the Semi business is going to be tempered a little bit by another decrease in the contamination control but overall Semi will be up in the December quarter so maybe they were clear in the prepared remarks from that standpoint.

And then on the 4titude benefit effect on the guidance?

Yeah. So let me put just a little more just context on both sides, so we see that there's a possibility of Semi side could be approximately flat, but it could be down slightly and we're managing, we always manage. What the customer takes is there's always a range around. And then on the Life Science side, I gave you a number range of 47 to 49, that's up $3 million to $5 million. And we do factor in a little bit of growth in 4titude but when we have shared that the past 12 months, we saw about $14 million of revenue. So that would imply $3.5 million on a run rate, but frankly we don't factor all of that in the first quarter of an acquisition. I never count on a four-quarter revenue the first quarter I own a business because it's just logical previous owners flushed the pipeline. So we have a little modest growth in there on 4titude. We have some range on it and then we have some organic expansion and recall we had a 4, 3 months of PBMMI, so I don't get any incremental benefit from the 44 just on a quarter-to-quarter basis, but we're really solid on the likelihood of hitting that range 47 or 49.

Okay. That's helpful. And then I guess since we saw Life Sciences, I have question around the consumer business, I think you mentioned on the call, it's around $7 million this quarter and have seen decent growth. Have you started to see the synergy benefit from the customer because they are using a cold store and your position in market and have you seen either from your install business or from your BioStorage business that's driving the consumer growth?

Yeah. It would indeed we see pretty significant synergy benefits. As a matter of fact there's a new configuration of acoustic to this driving a meaningful part of our storage business. So from an order standpoint in future we're in a really strong position. Also we have two large store customers who are customers of the 4titude PCR plate and they store the PCR plates in our store. So we're seeing it is an overwhelming transformation for us to be going to have a conversation with customers on all aspects of the portfolio or especially see it on the order side for consumables and we anticipate in 2018 that the revenue lift will come as a result of the synergy that we have.

Yeah, definitely it does, it seems like this is a good a good driver going forward. And last question I have on the margin side, very strong this quarter and if I look at your target model slight you are frankly quite consoled to in terms your margin outlook on for example your gross margin side, you are trending at that and you already guided for your Life Science gross margin go higher and then similarly on the operating margin side I think historically you said Life Science operating margin should be trending up above corporate average, are you guys trying to be conservative there, can you break that down for us a little bit?

Yeah. So it's a really fair question because I put on the page about 41% and I told you that the Semi business would be about 41% and the Life Sciences would be 42% to 44%. At the low end of the range it will still be above 41%. I should say on low end of that Life Science range it will average about 41% and the high end it could be a little bit higher in the mix of the business. Why at 41% on the semi when we just struck 42%? We did have some favorable mix as I highlighted in my prepared remarks in the quarter. We're not shying away from taking this thing upward in fact our segment leader Dave Jarzynka is very focused on driving margin optimization and we've got continued actions on cost as well as value of the product. But we're also cautious on a window like this of two years that we've not been in this territory before, we're quite pleased to be above 40% in over the year are competent that will be above that for it's coming assuming the revenue in the market holds for us. But it'll vary as some on mix, some on the strength of the market and the cycle. So you're fair we're being a little cautious on the semi, it's a sustain model right now on the margins from where we're operating, but still significant improvement from the annual average we just had over the last four quarters.

Okay. Great. Just quickly follow-up on the operating margin side, the target for 18% you expect Life Science to be above or below that all any kind of way to think about Life Science and Semi versus the target?

Yeah. It's a good question and I'll take that on. So in our 2019 a year ago, we told you that 2019 might be the year the Life Science overcomes semi that the time we were calling for 15% Semi objective and Life Scientists a bit higher. Right now, we've adjusted our perspective on this. We think Semi is running above 16% already and on a consistent basis. So we think that we will continue to support that on the semi site assuming we're in the range of revenue. On the Life Sciences, we've backed off a little bit on that. In other words do we think we get this to 15%? Yeah, we expect so but in our model. But I will tell you that as we've come through this year, we've seen opportunities to make investment to grow profitably to expand the foundation for future profitable growth with a lot of confidence and we're seeing that opportunity continues. So our commitment in this model is that we will sustain and improve the operating margins each year, but I don't think 2019 will be the year likely that we crossover absent a significant change in the acquisitions that we do go is going forward.

Okay great, that's all I have, appreciate it.

Thank you. Our next question comes from Patrick Ho with Stifel. Please proceed.

Hi this is Brian Chin calling in for Patrick. Thanks for letting me ask a few questions. First question just going back to the Semiconductor business, just curious the business tracking around 20% growth year-on-year, if you exclude those headwinds you alluded to the licensing revenue and the wind down at the JV. Just curious what would that Semi revenue growth have been fiscal year over fiscal year?

I think it probably would added about three to four points of growth, in other words estimating it was approximately $20 million in the previous year. And if you would add that back and estimating I'll double check the arithmetic here, but in round numbers, it would have had about a four point drag on the revenue likely.

Okay. That's helpful. I guess also, when you talk about perhaps there could be some volatility, variability in the Semi business, but as you alluded to relative to two or three years back and certainly six or seven years ago, the business is much stronger, and it looks like it's much more sustainable even if there is variability, it's going to be up much higher level. Just curious to what extent that really is adjusting your strategy in the Life Sciences business. I would think you kind of put you more towards a posture being even more aggressive maybe the term loan agreement is evidence of this. Just hope you can comment little more on that?

I think you have it right. We rather deliver and take action and let you know some of the things, but we see tremendous growth potential. Right now, we have a new organization fitting into what we see is just a global expansion. We have systems this year we signed off in Sweden, in Qatar, in Australia, in Korea, in Japan, we have a really strong global footprint and we're stretching the organization pretty hard. We're adding capability as quickly as we can. As you surmise obviously the debt we took on positions us really well to continue to expand. And our ambitions are pretty significant growth. And we'll signal to you, as we get closer but as we take on more transactions as Lindon mention is one of the reasons we're updating the model right now as we transform the business pretty significantly. And I would anticipate a year from now, we'll have more conversation about new models, especially around the Life Sciences side. Brian, you exactly right, we're positioned to continue to take advantage of what's a tremendous opportunity here.

Brian and I would come back, I already got corrected in the room the revenue in the previous year related to Life Science income as well as the distribution agreement that we accepted in was about a six-point headwind growth rate.

That's helpful. Maybe one last quick thing, going into the target model that you updated today, in the revenue at the midpoint I think up something like 8% relative to the midpoint of the prior model from over a year ago. I did know it's the higher than EPS range lower one increase the higher of the range state the same inside the midpoint increase, just curious why the higher end of the EPS range did not change?

So Brian, we are a year further along into the model and, so we take a sharper pencil you'll see the ranges on all lines I think narrowed just a bit and this is where we're estimating it today. I want to emphasize another point as we folded in about $0.10 the year for the interest expense and so that was in the previous, so you would see the high end $0.10 higher if we didn't have carry the debt. And as I highly as we expect to put that money to use but we haven't factored in the benefits, it wouldn't be unlikely that we could add, it's certainly EBITDA and non-GAAP EPS to the model to that range.

Thank you, so much, appreciate it.

Thank you for your analysis.

[Operator Instructions] Our next question comes from the line of Amanda Scarnati with Citi. Please proceed.

Hi good morning. Just a question on the new agreement in China and the investments that are required there. Are these sort of one-time investment that have to happen and kind of growth the business overall in China or as you continue to gain more market share and more companies within China, will you use these investments kind of increasing as you go along?

We think this is one very specifically for a target that we feel is really important. There are lot of opportunities we have in China that we made, what we think is a really solid package and agreement with a customer to get ourselves establish firmly. So we think it's one time. We think the next expansion opportunities that come as a result will be more consistent steady business, but we are making some investment both from a configuration standpoint and we might issue our volume that we know we want to make sure that we in and secure. So it's just going to be lower margin at the first part and we think it will reestablishes as soon as we get to the next opportunities that exist there and it will be the reference for us in China. So we think it's got a lot of value finance standpoint as well.

So are you giving some sort of like pricing concessions in the investment packages you're giving them or is this adding infrastructure for them? Can you talk little bit more about what these investments are?

Yeah, I can't talk too much, but in our ability to get the stores and we are making some configuration changes if you will and so that's a good start for us, happens on the first time of these tools but will be a good thing for us to move going forward.

Okay. And then as you look at Semi business going forward through 2019, what product line do you look at as kind of the greatest growth potential for Brooks? Are there any product areas that you're little bit concerned about going through 2019?

For us that as long as the vacuum processes continue to dominate that's really important. We see the contamination control as extremely strong. Amanda if there's a question mark its where we go beyond boundaries as very significant consumers of contamination control and will that fanned out into some of the memory and some of the other logic at the same kinds of levels. That's probably an upside opportunity more than anything, but that's an open question that we have. And we're investing pretty significantly in the advance packaging. So we see those three vectors, the vacuum, automation, the contamination control and advance packaging continuing, certainly in time frame of the 2020. We do pay attention to the discontinuity that could happen at EUV, but I remind you we have the EUV business also that's related to the radical management in the pod and pod cleaning. So even if that diminishes slightly the amount of deposition in that because you can do single pattern for example to we can reduce the number of event logic to form the transistor. We have an additional piece of business, we think that will come pretty significantly around EUV. So we think we're positioned properly, we do spend a lot of time with our customers on the next generation of capabilities but as long as the deposition and etch continues to grow like it does, we think we're positioned really well.

Great, thank you.

Thank you. Our next question comes from line of Craig Ellis with B. Riley FBR. Please proceed.

Yeah, thanks for taking the question and guys congratulations on stellar fiscal 2017 execution across both businesses. I wanted to start following up with your detailed comments on the Semi business Steve, you outlined the strength that you saw across the four parts of that business in fiscal 2017, not looking for guidance here, but can you just talk about growth gives and takes as you look out over 2018 across vacuum, automation, advanced packaging, CCS and cryo vac?

Sure. Craig it's interesting pattern through the year, a lot of people saw growth and one thing that's curious one for us in the vacuum automation, we saw four quarters almost at the same level every quarter. When we had the vacuum robots in the vacuum systems it was strong from the get go. So from Q1 through Q4 and we anticipate the depth that approximately that level is what we would anticipate at least starting 2018. So that's really healthy and we think that's exactly a measure of the deposition add strength and it has more memory, 3D memory gets added, we anticipated that business will continue to be strong. On the advanced packaging this is up and down a little bit more but where TSMC the first of the info lines went in, we had a very significant presence there because we gained share with the participants and we think that the next line that becomes will drive similar amount of business, the advantage we think that we have is because the same suppliers of equipment who use our capabilities are going to supply OSAP and some of the device makers whomever on advance packaging as that capability ramps up beyond TSMC, we anticipate that lot of drive the business, we have less visibility there frankly but we think that's just generally the trend. On the contamination control again, when advance foundries begin to spend that will be strong, we are watching very carefully on the ability to penetrate memory but we right now if you were going get us to take a look at it a strong $80 million a year might look similar in 2018 for right now, just to give you a sense. And as I mentioned on there, chiller cryo pump side, strong into Q4 and Q1 feels similar from and how we are going to start fiscal Q1 2018

That's great. And then the next question I have is regarding life science I think the question I get most from investors now is regarding the M&A strategy broadly and specifically there. So what I was hoping you could do Steve is one how can you just step back in from a higher level given the transaction history of the company, talk about where you are in terms of your comfort with deals from a size and pacing standpoint given that we just had three deals and relative to the three life sciences initiatives, that you outlined on the call. Should we think about M&A targeted at those initiatives or is the list of priorities somewhat different in those three initiatives going forward?

Sure. Right now it remains different I'll explained here. We have a complete cold chain I think that's one of things we tried to emphasize from an acquisition of samples standpoint, formatting transport, storage services, and Informatics it's a very complete portfolio and we have an analysis capability now as a result of the bio storage alliance we have with Rutgers. So we really have the ability to manage the samples from a cold chain standpoint. One of the things that the cryo brings to us is the ability to extend the cold chain to another temperature range and participate with a whole different set of applications really related to immunotherapy. So we have a foundation of the business that but applying some of that capability at a different temperature range opens up the next level of opportunity for us, so most of what we have is there because it's a new field it's the development of products that we are bringing to market, that allows us to participate. And so you may see some acquisitions there but mostly that would be organic and as we always mention this is a very fragmented space and the advantages that accrue to us, as being someone who can provide a complete solution we are looking at always like a company like a PBMMI that adds more samples into a model that already exists to an infrastructure that already exists. So as there are things that we can do from a consolidation standpoint where smaller companies fit our model and we could drive both synergies and a little bit more reach we'll be looking at those two. All that said, there are some things that we'll also consider from a transformative standpoint, and we think we have the capacity if that an appropriate accretive opportunity came that we would consider a transformative deal, but right now the kind of things you will see is doing are more along the consolidation of the kinds of capabilities we have but if the Informatics platform could be advanced by a few more capabilities we'd add in rather than develop will do that and if it doesn't make sense we have the development capability to do that on our own.

That's really helpful and the last question is to Lindon. Lindon as I look at the target model and your comments around the changes there too it seems like there was not one thing that drove the update on either the life sciences or the semi side, but it was an update driven by developments there and then just change in some of the income statement items like interest expense, Is it that there or was there really a particular driver as you thought about updating the model on this call versus a quarter from now or three months ago?

It really reflects the combination of everything because what we've seen is the semi spaces change significantly in terms of the level of CapEx in the market and our revenue sustainability as well as the number of acquisitions we've added to the life sciences. So if I stick with the old model I keep bridging people back with these differences and changes and whereas that there was time obviously factoring in the interest expense I think is important for people to understand what's happening. So we bring some clarity on that Craig, so I think it's a combination of all of these and I would emphasize that the model while it carries the cost of the debt is not yet carrying the benefit of future acquisitions, we have a nice pipeline in front of us. So we expect to fill that in but it's a combination of all those factors that drove the uptick.

Great. Thank you.

And there are no further question. Mr. Robertson. I'll turn the call back to for any closing remarks.

Okay. Thank you Nelson, and thank you everyone for your time spent with us we have what we believe is a really solid progress and outstanding year of performance we had an outlook that takes us up a bit in the revenue and we will hold our earnings approximately similar when considering the interest cost and then we're pleased to move forward on that basis and also in emphasis the outlook that we have is we build the model out, I mean you seeing the progress over the past year, we see there is much more progress to be made coming 2018 fiscal year going in 2019. And we have a lot of confidence where we're headed, and we thank you for your time and considerations of Brooks Automation. So thank you and we wish everyone the best for the holiday season ahead.

Ladies and gentlemen that does conclude the conference call for today. We thank you for your participation and ask that you please disconnect your line.